Results 121 to 130 of about 25,074 (200)

SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. [PDF]

EMBO Mol Med
Cho HJ, Smith J, Switzer CH, Louka E, Charles RL, Prysyazhna O, Schroder E, Fernandez-Caggiano M, de Jesus DS, Eminaga S, Yin X, Yang X, Lynham S, Mayr M, Morales V, Bianchi K, Rajeeve V, Cutillas PR, Mead AJ, Eaton P.   +19 more
europepmc   +1 more source

Clinical course and short-term outcome of postsplenectomy reactive thrombocytosis in children without myeloproliferative disorders: A single institutional experience from a developing country. [PDF]

PLoS One, 2020
Zvizdic Z, Kovacevic A, Milisic E, Jonuzi A, Vranic S.   +4 more
europepmc   +1 more source

The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia. [PDF]

Cureus
Sayed WS, Al-Bayati A, Elzubair LG, Mohamed S, Alharthi M.   +4 more
europepmc   +1 more source

[The role of AKT inhibitors combined with Ruxolitinib in ameliorating myeloproliferative disorders in mice with CALR gene mutations]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Zhang LW, Zhang QG, Ji MC, Qi KM, Li ZY, Xu KL, Fu CL.   +6 more
europepmc   +1 more source

Four Cases of Myeloproliferative Disorders Associated With Down Syndrome: Distinguishing ML-DS From TAM-DS: Distinguishing TAM-DS and ML-DS: Report of 4 Cases. [PDF]

Case Rep Hematol
Boumeghar K, Daliphard S, Buchbinder N, Boutet C, Penther D, Etancelin P, Bourgain J, Buchonnet G, Bera E, Bobée V.   +9 more
europepmc   +1 more source

JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population. [PDF]

Asian Pac J Cancer Prev, 2019
Syeed N.
europepmc   +1 more source

Pairing JAK with MEK for improved therapeutic efficiency in myeloproliferative disorders. [PDF]

J Clin Invest, 2019
Williams DA.
europepmc   +1 more source

Myelodysplastic and myeloproliferative disorders of childhood. [PDF]

Hematology Am Soc Hematol Educ Program, 2016
Hasle H.
europepmc   +1 more source

Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders. [PDF]

Clin Appl Thromb Hemost, 2018
Yildiz A, Güryildirim M, Pepeler MS, Yazol M, Oktar SÖ, Acar K.   +5 more
europepmc   +1 more source

Prevalence of Physical Problems Detected by the Distress Thermometer and Problem List in Patients With Myeloproliferative Disorders. [PDF]

J Natl Compr Canc Netw, 2017
McFarland DC, Shaffer KM, Polizzi H, Mascarenhas J, Kremyanskaya M, Holland J, Hoffman R.   +6 more
europepmc   +1 more source